Essential medicines and better, diverse solutions to disruptions in the US drug supply caused by the COVID-19 pandemic were the main topics of the National Academy of Science, Engineering, and Medicine's (NAS) public workshop held by its Security of America's Medical Product Supply Chain committee this week.This was the second meeting by the committee, which was created as part of the COVID-focused CARES Act to provide recommendations regarding the US medical supply chain.The panelists included representatives from Civica Rx, Vizient, government and public health agencies, the American Hospital Association, the American Society of Hospital Pharmacists (ASHP), and the Resilient Drug Supply Project (RDSP), which is a part of the University of